614 related articles for article (PubMed ID: 25211298)
21. Glioblastoma: synergy of growth promotion between CCL5 and NK-1R can be thwarted by blocking CCL5 with miraviroc, an FDA approved anti-HIV drug and blocking NK-1R with aprepitant, an FDA approved anti-nausea drug.
Kast RE
J Clin Pharm Ther; 2010 Dec; 35(6):657-63. PubMed ID: 21054456
[TBL] [Abstract][Full Text] [Related]
22. Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma.
Reardon DA; Vredenburgh JJ; Desjardins A; Peters K; Gururangan S; Sampson JH; Marcello J; Herndon JE; McLendon RE; Janney D; Friedman AH; Bigner DD; Friedman HS
J Neurooncol; 2011 Jan; 101(1):57-66. PubMed ID: 20443129
[TBL] [Abstract][Full Text] [Related]
23. Disulfiram when Combined with Copper Enhances the Therapeutic Effects of Temozolomide for the Treatment of Glioblastoma.
Lun X; Wells JC; Grinshtein N; King JC; Hao X; Dang NH; Wang X; Aman A; Uehling D; Datti A; Wrana JL; Easaw JC; Luchman A; Weiss S; Cairncross JG; Kaplan DR; Robbins SM; Senger DL
Clin Cancer Res; 2016 Aug; 22(15):3860-75. PubMed ID: 27006494
[TBL] [Abstract][Full Text] [Related]
24. Molecular analysis of a recurrent glioblastoma treated with bevacizumab.
Furuta T; Nakada M; Misaki K; Sato Y; Hayashi Y; Nakanuma Y; Hamada J
Brain Tumor Pathol; 2014 Jan; 31(1):32-9. PubMed ID: 23504126
[TBL] [Abstract][Full Text] [Related]
25. Cordycepin Augments the Chemosensitivity of Human Glioma Cells to Temozolomide by Activating AMPK and Inhibiting the AKT Signaling Pathway.
Bi Y; Li H; Yi D; Sun Y; Bai Y; Zhong S; Song Y; Zhao G; Chen Y
Mol Pharm; 2018 Nov; 15(11):4912-4925. PubMed ID: 30336060
[TBL] [Abstract][Full Text] [Related]
26. Current chemotherapy for glioblastoma.
Parney IF; Chang SM
Cancer J; 2003; 9(3):149-56. PubMed ID: 12952300
[TBL] [Abstract][Full Text] [Related]
27. Artesunate enhances the antiproliferative effect of temozolomide on U87MG and A172 glioblastoma cell lines.
Karpel-Massler G; Westhoff MA; Kast RE; Dwucet A; Nonnenmacher L; Wirtz CR; Debatin KM; Halatsch ME
Anticancer Agents Med Chem; 2014 Feb; 14(2):313-8. PubMed ID: 24506460
[TBL] [Abstract][Full Text] [Related]
28. SK channel activation potentiates auranofin-induced cell death in glio- and neuroblastoma cells.
Krabbendam IE; Honrath B; Bothof L; Silva-Pavez E; Huerta H; Peñaranda Fajardo NM; Dekker F; Schmidt M; Culmsee C; César Cárdenas J; Kruyt F; Dolga AM
Biochem Pharmacol; 2020 Jan; 171():113714. PubMed ID: 31738894
[TBL] [Abstract][Full Text] [Related]
29. NEO212, a conjugate of temozolomide and perillyl alcohol, blocks the endothelial-to-mesenchymal transition in tumor-associated brain endothelial cells in glioblastoma.
Marín-Ramos NI; Jhaveri N; Thein TZ; Fayngor RA; Chen TC; Hofman FM
Cancer Lett; 2019 Feb; 442():170-180. PubMed ID: 30392789
[TBL] [Abstract][Full Text] [Related]
30. Disulfiram, a drug widely used to control alcoholism, suppresses the self-renewal of glioblastoma and over-rides resistance to temozolomide.
Triscott J; Lee C; Hu K; Fotovati A; Berns R; Pambid M; Luk M; Kast RE; Kong E; Toyota E; Yip S; Toyota B; Dunn SE
Oncotarget; 2012 Oct; 3(10):1112-23. PubMed ID: 23047041
[TBL] [Abstract][Full Text] [Related]
31. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme.
Groves MD; Puduvalli VK; Hess KR; Jaeckle KA; Peterson P; Yung WK; Levin VA
J Clin Oncol; 2002 Mar; 20(5):1383-8. PubMed ID: 11870183
[TBL] [Abstract][Full Text] [Related]
32. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.
Weller M; Butowski N; Tran DD; Recht LD; Lim M; Hirte H; Ashby L; Mechtler L; Goldlust SA; Iwamoto F; Drappatz J; O'Rourke DM; Wong M; Hamilton MG; Finocchiaro G; Perry J; Wick W; Green J; He Y; Turner CD; Yellin MJ; Keler T; Davis TA; Stupp R; Sampson JH;
Lancet Oncol; 2017 Oct; 18(10):1373-1385. PubMed ID: 28844499
[TBL] [Abstract][Full Text] [Related]
33. COXIBs and 2,5-dimethylcelecoxib counteract the hyperactivated Wnt/β-catenin pathway and COX-2/PGE2/EP4 signaling in glioblastoma cells.
Majchrzak-Celińska A; Misiorek JO; Kruhlenia N; Przybyl L; Kleszcz R; Rolle K; Krajka-Kuźniak V
BMC Cancer; 2021 May; 21(1):493. PubMed ID: 33941107
[TBL] [Abstract][Full Text] [Related]
34. Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677.
Ratai EM; Zhang Z; Snyder BS; Boxerman JL; Safriel Y; McKinstry RC; Bokstein F; Gilbert MR; Sorensen AG; Barboriak DP
Neuro Oncol; 2013 Jul; 15(7):936-44. PubMed ID: 23645534
[TBL] [Abstract][Full Text] [Related]
35. Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme.
Hainsworth JD; Ervin T; Friedman E; Priego V; Murphy PB; Clark BL; Lamar RE
Cancer; 2010 Aug; 116(15):3663-9. PubMed ID: 20564147
[TBL] [Abstract][Full Text] [Related]
36. Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study.
Boxerman JL; Zhang Z; Safriel Y; Larvie M; Snyder BS; Jain R; Chi TL; Sorensen AG; Gilbert MR; Barboriak DP
Neuro Oncol; 2013 Jul; 15(7):945-54. PubMed ID: 23788270
[TBL] [Abstract][Full Text] [Related]
37. RTOG 0913: a phase 1 study of daily everolimus (RAD001) in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma.
Chinnaiyan P; Won M; Wen PY; Rojiani AM; Wendland M; Dipetrillo TA; Corn BW; Mehta MP
Int J Radiat Oncol Biol Phys; 2013 Aug; 86(5):880-4. PubMed ID: 23725999
[TBL] [Abstract][Full Text] [Related]
38. Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.
Chong DQ; Toh XY; Ho IA; Sia KC; Newman JP; Yulyana Y; Ng WH; Lai SH; Ho MM; Dinesh N; Tham CK; Lam PY
BMC Cancer; 2015 Apr; 15():255. PubMed ID: 25886314
[TBL] [Abstract][Full Text] [Related]
39. A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme.
Groves MD; Puduvalli VK; Chang SM; Conrad CA; Gilbert MR; Tremont-Lukats IW; Liu TJ; Peterson P; Schiff D; Cloughesy TF; Wen PY; Greenberg H; Abrey LE; DeAngelis LM; Hess KR; Lamborn KR; Prados MD; Yung WK
J Neurooncol; 2007 Feb; 81(3):271-7. PubMed ID: 17031561
[TBL] [Abstract][Full Text] [Related]
40. Local intracerebral administration of O(6)-benzylguanine combined with systemic chemotherapy with temozolomide of a patient suffering from a recurrent glioblastoma.
Koch D; Hundsberger T; Boor S; Kaina B
J Neurooncol; 2007 Mar; 82(1):85-9. PubMed ID: 17031555
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]